AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Phase II colorectal trial results for Theratope vaccine to be presented at ASCO.(Biomira Inc. colorectal cancer vaccine)
2003 APR 16 - (NewsRx.com & NewsRx.net) -- Biomira, Inc., (BIOM; BRA) announced that data from the company's phase II Theratope vaccine trial in metastatic colorectal cancer will be presented as a poster presentation at the 2003 Annual Meeting of ASCO.
The 20-patient colorectal trial completed enrollment in October 2002. The trial was conducted at the Cross Cancer Institute, Edmonton, AB. The lead investigator and ASCO presenter is Charles Butts of the Cross Cancer Institute. The trial was designed to evaluate the safety of the vaccine in patients with metastatic colorectal cancer, as well as to evaluate the ability of the vaccine to induce an immune response in these patients when given in combination with first line chemotherapy. The 2003 Annual Meeting abstracts are expected to be publicly available immediately following the meeting on Tuesday, June 3, 2003.
"ASCO received more than 3,700 abstracts this year for review by the Scientific Program Committee. We are very pleased that Butts' abstract was accepted and this will be the venue for presenting the results from this phase II trial. This was our first opportunity to accumulate data using Theratope in combination with chemotherapy. We will be closely studying the results of this trial as we await the final results from our phase III Theratope trial in 1,030 women with metastatic breast cancer. We anticipate those phase III results to be announced towards the end of the first half of 2003," said Alex McPherson, MD, PhD, president and CEO of Biomira.
Biomira has also been ...
- ISTA Pharmaceuticals Announces Vitrase Phase III Data to Be Presented at Annual...
- Press release article from: PR Newswire April 23, 2004 700+ words
...concerning data from Phase III clinical trials of Vitrase...presented at the 2004 annual meeting of the Association for...Integrated results from 2 Phase III studies. Presentation...an Ex-North America Phase III Study. Presentation...
- AACR Annual Meeting Phase III Biomarker Data Predict Advexin Efficacy in Some...
- Magazine article from: BIOWORLD Today Young, Donna April 15, 2008 700+ words
...that preliminary data of a Phase III trial showed that Advexin...presented its preliminary Phase III results Sunday in San Diego at the annual meeting of the American Association...Fraumeni syndrome. In the Phase III recurrent head and neck...
- ISTA Pharmaceuticals Presents Vitrase Phase III Data Analysis at Retina Society...
- Press release article from: PR Newswire September 22, 2003 700+ words
...announced that the Company presented integrated data from two Phase III clinical trials of Vitrase(R) (ovine hyaluronidase...presentation was made on Saturday, September 20th at the Annual Meeting of the Retina Society in Chicago. The integrated results...
- MGI PHARMA & HELSINN Summarize Aloxi -Palonosetron HCl Injection- Phase III...
- Press release article from: Business Wire June 2, 2003 700+ words
...presentations made during the 39th Annual Meeting of the American Society of...presentations described data from phase III pivotal trials of the companies...primary endpoint in the pivotal phase III clinical trials of palonosetron...FDA. "The results of the phase III ...
- ISTA Pharmaceuticals Presents Vitrase Phase III Data at American Academy Of...
- Press release article from: PR Newswire November 19, 2003 700+ words
...presented integrated data from two Phase III clinical trials of Vitrase(R...Saturday, November 15th at the Annual Meeting of the American Academy of Ophthalmology...a 55 IU dose of Vitrase. These Phase III clinical results were previously...
- Isotechnika's Phase III psoriasis trial data to be presented at both the...
- Press release article from: PR Newswire March 2, 2006 700+ words
...Function in a Phase III Trial' at the...Transplantation Annual Meeting. Mr. Huizinga...the Company's Phase III psoriasis trial...of Dermatology Annual Meeting in San Francisco...presentation entitled 'A Phase III, Randomized...
- MGI PHARMA & HELSINN Announce Upcoming Presentations of Phase III Clinical Data...
- Press release article from: Business Wire May 27, 2003 700+ words
...announced that phase III data will be presented...palonosetron at the 39th Annual Meeting of the American...provide insight into Phase III pivotal data for...the 2003 ASCO annual meeting: Title: Palonosetron...Results of a phase III trial Integrated...
- Delcath Reports On 2003 Annual Meeting; Accrual For Phase III Trial Expected To...
- Press release article from: PR Newswire June 5, 2003 700+ words
...shareholders voting at the company's 2003 Annual Meeting in Greenwich, CT yesterday voted in...will be used for funding the launch of Phase III clinical trials, for continuing clinical...accrual to start soon for the company's Phase III pivotal trial using the drug doxorubicin...